Skip to main content

Table 5 Distribution of study participants according medical/medication history, Women Hospital-Hamad Medical Corporation, 2018

From: Risk profile of Qatari women treated for infertility in a tertiary hospital: a case-control study

Medical/ Medication history

Cases

Cases

Controls

p value

Primary Infertility

n = 43 (%)

Secondary Infertility

n = 93 (%)

Infertility Total

n = 136 (%)

n = 272 (%)

Hypothyroidism:

0.025*

 No

35 (81.4)

75 (80.6)

110 (80.9)

242 (89.0)

 Yes

8 (18.6)

18 (19.4)

26 (19.1)

30 (11.0)

Hyperprolactinemia:

0.001*

 No

34 (79.1)

78 (83.9)

112 (82.4)

255 (93.8)

  Yes

9 (20.9)

15 (16.1)

24 (17.6)

17 (6.2)

Depression and/or other psychological disorders:

0.002*

 No

40 (93.0)

88 (94.6)

128 (94.1)

270 (99.3)

  Yes

3 (7.0)

5 (5.4)

8 (5.9)

2 (0.7)

Polycystic ovarian syndrome:

0.001*

 No

21 (48.8)

43 (46.2)

64 (47.1)

220 (80.9)

 Yes

22 (51.2)

50 (53.8)

72 (52.9)

52 (19.1)

Fibroid uterus:

0.026*

 No

37 (86.0)

86 (92.5)

123 (90.4)

261 (96.0)

  Yes

6 (14.0)

7 (7.5)

13 (19.6)

11 (4.0)

Appendectomy

0.035*

  No

41 (95.3)

84 (94.3)

125 (91.9)

263 (96.7)

 Yes

2 (4.7)

9 (9.7)

11 (8.3)

9 (3.3)

Prolonged steroid:

0.050*

 No

42 (97.7)

84 (90.3)

126(92.6)

267 (98.2)

  Yes

1 (2.3)

9 (9.7)

10 (7.4)

5 (1.8)

Hormonal therapy:

0.001*

 No

15 (34.9)

19 (20.4)

34 (25.0)

260 (95.6)

 Yes

28 (65.1)

74 (79.6)

102(75.0)

12 (4.4)

Prolonged high dose of NSAID:

0.001*

 No

40 (93.0)

78 (83.9)

118(86.8)

261 (96.0)

 Yes

3 (7.0)

15 (16.1)

18 (13.2)

11 (4.0)

Anti-obesity

(Xenical®,Meridia®):

0.001*

 No

42 (97.7)

81 (87.1)

123(90.4)

267 (98.2)

 Yes

1 (2.3)

12 (12.9)

13 (9.6)

5 (1.8)

  1. * p < 0.05
  2. NSAID Non-Steroidal Anti Inflammatory Drugs
  3. Xenical® is the trade name for Orlistat, Meridia® is the trade name for Sibutranine